ArticleJournal of hematology & oncology2019
Burden of lymphoma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016.
Article in Journal of hematology & oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06830031 (A Phase 1 Study of C402-CD19-CAR, a Chimeric Antigen Receptor T Cell), which is not on this map. Cited by 61 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1 Study of C402-CD19-CAR, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Targeting CD19 in Subjects With Relapsed or Refractory Large B-cell Lymphoma
Who cites it
61 citing papers in PubMed, 4 syntheses or guidelines pooled it, 146 citations in OpenAlex.
- Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis.Annals of hematology · 2023Pooled it
- Prophylaxis forBMJ open · 2023Pooled it
- Meta-Analysis of Risk Factors and Incidence of Interstitial Pneumonia With CHOP-Like Regimens for Non-Hodgkin Lymphoma.Frontiers in oncology · 2022Pooled it
- Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study.Frontiers in public health · 2021Pooled it
- Trial
- The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.Cancer medicine · 2021Trial
- Clinical characteristics and risk factors for mortality in pulmonary mucormycosis among patients with non-hematologic malignancies.BMC pulmonary medicine · 2026Article
- Trends and future projections of Hodgkin and Non-Hodgkin lymphoma burden in Chinese children and adolescents (1990-2043): insights from the GBD 2023 database.Annals of hematology · 2026Article
- Hematologic malignancies burden in China compared with the United States 1990-2021 and projections to 2040.Discover oncology · 2026Article
- [Analysis of the disease burden of Burkitt lymphoma in China from 1990 to 2021].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- A Phase II Study ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Risk and Survival Outcomes of Secondary Primary Malignancies in Chinese Lymphoma Patients in the Era of Modern Targeted Therapies: A Single-Center Retrospective Cohort Study.Blood and lymphatic cancer : targets and therapy · 2026Article
- Burden of Hematological Malignancies in East Asia from 1990 to 2021.Journal of clinical medicine · 2025Article
- Minimal clinically important difference of EQ-5D-5L, SF-6Dv2, and QLU-C10D in hematologic malignancy patients in China.Health and quality of life outcomes · 2025Article
- Comparative study of early onset cancer burden between China and the United States from 1990 to 2021.Scientific reports · 2025Article
- Global burden of Hodgkin lymphoma among children and adolescents: a population-based study using GBD 2021.Frontiers in pediatrics · 2025Article
- Diagnosis, clinical features, and mortality risk factors in a Chinese cohort with pulmonary mucormycosis.PloS one · 2025Article
- Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Global, regional, and national burden of gastrointestinal cancers among adolescents and young adults from 1990 to 2019, and burden prediction to 2040.BMC public health · 2024Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe accurate information about lymphoma burden at national and provincial levels remains unknown in China.
methodsFollowing the general analytical strategy used in GBD 2016, the age-, sex-, and province-specific incidence, mortality, and prevalence of lymphoma in China were analyzed. Trends in the incidence, mortality, prevalence, and disability-adjusted life years (DALYs) due to Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL) were assessed from 2006 to 2016.
resultsIt was estimated that there were 75,400 new cases and 40,500 deaths of lymphoma in 2016 in China, of which 6900 new cases and 2900 deaths were due to HL, while 68,500 new cases and 37,600 deaths were due to NHL. The age-standardized incidence rate (ASIR), mortality rate (ASMR), and prevalence rate (ASPR) per 100,000 were 0.46, 0.19, and 1.75 for HL, and 4.29, 2.45, and 14.9 for NHL, respectively. An upward trend with age in incidence and mortality was observed. Males had higher incidence and mortality rates than females in all age groups. Sociodemographic index had a correlation with the ASIR (r = 0.75), ASMR (r = - 0.74), ASPR (r = 0.84), and age-standardized DALYs (r = - 0.75) of HL, as well as with the ASIR (r = 0.80), ASPR (r = 0.83), and age-standardized DALYs (r = - 0.33) of NHL. From 2006 to 2016, the age-standardized DALYs of HL decreased significantly, while the age-standardized DALYs of NHL increased from 2006 to 2013 and remained stable from 2013 to 2016.
conclusionsThe burden of lymphoma in China showed unexpected patterns varied by sex, age, and provinces, with an increased trend of NHL and a decreased trend of HL from 2006 to 2016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.